INCY
Incyte Corp.

5,401
Loading...
Loading...
News
all
press releases
Incyte Announces Phase 1 Results for its TGFR2PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma
Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFR2PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent...
Business Wire·7h ago
News Placeholder
More News
News Placeholder
INCY or ARGX: Which Is the Better Value Stock Right Now?
INCY vs. ARGX: Which Stock Is the Better Value Option?
Zacks·3d ago
News Placeholder
Data from Incytes TGFR2PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the European Society of Medical Oncology (ESMO) Congress 2025
Incyte (Nasdaq:INCY) today announced that results from Phase 1 proof-of-concept studies of INCA33890, a promising TGFR2PD-1-directed bispecific antibody, and INCB161734, a novel, selective and orally...
Business Wire·7d ago
News Placeholder
Abbott to Report Q3 Earnings: Medical Devices Arm in Focus
ABT's Q3 results may show strength in Medical Devices and Nutrition, offsetting softness in Diagnostics.
Zacks·9d ago
News Placeholder
TLRY Gears Up to Report Q1 Earnings: Cannabis Recovery in Focus
Tilray Brands' fiscal first-quarter report is likely to highlight international cannabis gains, European expansion and wellness growth.
Zacks·11d ago
News Placeholder
Will Incyte (INCY) Beat Estimates Again in Its Next Earnings Report?
Incyte (INCY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zacks·12d ago
News Placeholder
INCY vs. ARGX: Which Stock Is the Better Value Option?
INCY vs. ARGX: Which Stock Is the Better Value Option?
Zacks·19d ago
News Placeholder
Strength Seen in Oculis Holding AG (OCS): Can Its 6.7% Jump Turn into More Strength?
Oculis Holding AG (OCS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Zacks·26d ago
News Placeholder
INCY Obtains FDA Approval for Label Expansion of Ruxolitinib Cream
Incyte secures FDA nod for Opzeluras pediatric use in atopic dermatitis, marking its third U.S. approval and boosting sales momentum.
Zacks·1mo ago
News Placeholder
INCY Announces New Late-Stage Data on Skin Disease Drug
Incyte's povorcitinib shows strong 24-week STOP-HS data in hidradenitis suppurativa, supporting 2025-2026 regulatory filings.
Zacks·1mo ago

Latest INCY News

View

Advertisement|Remove ads.

Advertisement|Remove ads.